Shares in Clearside Biomedical (NSDQ:CLSD) fell today even though the biopharmaceutical company topped sales and earnings estimates on Wall Street with its fourth quarter and full year results.
The Alpharetta, Ga.-based company posted a net loss of -$16.5 million on sales of $55,000 for the three months ended Dec. 31, for bottom-line loss of -70% on sales growth of >100% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical posts Street-beating Q4, full year results appeared first on MassDevice.